Patient
portrayal

Learn about CABOMETYX
What is CABOMETYX?
CABOMETYX is a kind of medication called a tyrosine kinase inhibitor (TKI). It is given as a tablet.
It is used to treat:
- People with advanced kidney cancer alone or in combination with a medicine called OPDIVO® (nivolumab) if you have not already had treatment
How CABOMETYX may help
CABOMETYX is proven to help certain people with advanced kidney cancer in clinical studies.

In a clinical study, CABOMETYX was given to people with advanced kidney cancer as a first treatment (your doctor may call it “first-line treatment”), with another medicine, OPDIVO. Other people in the study received a different medicine, sunitinib.*
People stayed on treatment until their tumors started to grow, or they had a side effect that could not be managed.
In the study:

323 people took CABOMETYX (orally) + OPDIVO (infusion)

328 people took sunitinib (orally)
Each person’s results with CABOMETYX may be different.
CABOMETYX + OPDIVO results showed that:

People were able to live 2x LONGER without their tumors growing or spreading
People who took CABOMETYX + OPDIVO were able to live without their tumor progressing for a median† of 16.6 months compared with 8.3 months for people who took sunitinib.

TWICE AS MANY PEOPLE had meaningful reductions‡ in their tumor size
55.7% of people who took CABOMETYX + OPDIVO had reductions in tumor size compared to 27.1% of people who took sunitinib.
Nearly TWICE AS MANY PEOPLE saw their tumors disappear completely (complete response)
CABOMETYX + OPDIVO | sunitinib | |
---|---|---|
complete response | 8% | 4.6% |
partial response | 48% | 23% |
- *
-
Sunitinib is a medication used to treat people with advanced kidney cancer.
- †
-
Median is the middle value in a set of measurements—for some, it was shorter; for others, longer.
- ‡
-
Meaningful reductions defined as the combination of complete response (the disappearance of signs of cancer in response to treatment), and partial response (a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment).

CABOMETYX was proven to help certain people with advanced kidney cancer live longer without their tumor progressing.
CABOMETYX was compared with a medicine called sunitinib* in a clinical study of people with advanced kidney cancer. All people in the study had one or more established risk factors and had not previously received medicine to treat their cancer.
In the study:

79 people took CABOMETYX

78 people took sunitinib
People stayed on treatment until their tumor started to grow again or they had a side effect that could not be managed.
Each person’s results with CABOMETYX may be different.
CABOMETYX results showed that:

People were more likely to LIVE LONGER without their tumor growing or spreading
People who took CABOMETYX lived without their tumor progressing for a median† of 8.6 months compared with 5.3 months for people who took sunitinib.
- *
-
Sunitinib is a medication used to treat adults with advanced kidney cancer.
- †
-
Median is the middle value in a set of measurements—for some, it was shorter; for others, longer.

CABOMETYX was proven to help certain people with advanced kidney cancer
People had taken at least one other medicine to treat their advanced kidney cancer before taking CABOMETYX.
People stayed on treatment until their tumors started to grow or they had a side effect that could not be managed.
In the study:

330 people took CABOMETYX

328 people took a medicine called everolimus*
Each person’s results with CABOMETYX may be different.
CABOMETYX results showed that:

People were more likely to LIVE LONGER
People who took CABOMETYX lived a median† of 21.4 months compared with 16.5 months on everolimus.

People were able to live nearly 2X LONGER without their tumor growing or spreading
People who took CABOMETYX lived without their tumor progressing for a median of 7.4 months compared with 3.8 months for people who took everolimus.

More than 5X as many people saw their TUMOR SHRINK IN SIZE
17% of people who took CABOMETYX saw their tumor shrink in size compared with 3% of people who took everolimus. In the clinical study, the tumor had to shrink by at least 30% and had to be confirmed by a second scan. (Partial response‡ only.)
- *
-
Everolimus is a medication used to treat adults with advanced kidney cancer when certain other medicines have not worked.
- †
-
Median is the middle value in a set of the measurements—for some, it was shorter; for others, longer.
- ‡
-
Partial response is a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.

What are the possible side effects of CABOMETYX?
Taking CABOMETYX may cause side effects. The most common side effects of CABOMETYX include: tiredness, decreased appetite, nausea and vomiting, weight loss, and constipation.
The most common side effects of CABOMETYX when used with nivolumab include: tiredness, mouth sores, rash, low thyroid hormone levels (hypothyroidism), pain in muscles, bones, and joints, decreased appetite, nausea, changes in the way things taste, stomach-area (abdominal) pain, cough, and upper respiratory tract infection.
Learn about additional side effects, including serious side effects associated with CABOMETYX here.
LEARN MORE ABOUT

Patient Brochure
Download this resource to learn more about CABOMETYX, and help you discuss with your doctor if it is right for you.

The BE CONNECTED support program provides educational information for you or someone you are caring for who is taking CABOMETYX.
OPDIVO® and the related logo are registered trademarks of Bristol-Myers Squibb Company.